BACKGROUND: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. METHODS:Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. RESULTS: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.
RCT Entities:
BACKGROUND: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. METHODS: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. RESULTS: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.
Authors: Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona Journal: J Biol Chem Date: 2011-07-28 Impact factor: 5.157
Authors: Ruth A Karron; Roberta Casey; Bhagvanji Thumar; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt Journal: Pediatr Infect Dis J Date: 2011-10 Impact factor: 2.129
Authors: Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins Journal: Expert Rev Respir Med Date: 2011-08 Impact factor: 3.772
Authors: Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata Journal: Cochrane Database Syst Rev Date: 2017-05-18
Authors: Xiaoyan Zhan; Karen S Slobod; Sateesh Krishnamurthy; Laura E Luque; Toru Takimoto; Bart Jones; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz Journal: Vaccine Date: 2008-05-01 Impact factor: 3.641
Authors: Laurine C Rijsbergen; Katharina S Schmitz; Lineke Begeman; Jennifer Drew-Bear; Lennert Gommers; Mart M Lamers; Alexander L Greninger; Bart L Haagmans; Matteo Porotto; Rik L de Swart; Anne Moscona; Rory D de Vries Journal: mBio Date: 2022-02-15 Impact factor: 7.867
Authors: Janet A Englund; Ruth A Karron; Coleen K Cunningham; Philip Larussa; Ann Melvin; Ram Yogev; Ed Handelsman; George K Siberry; Bhavanji Thumar; Elizabeth Schappell; Catherine V Bull; Helen Y Chu; Anne Schaap-Nutt; Ursula Buchholz; Peter L Collins; Alexander C Schmidt Journal: Vaccine Date: 2013-10-05 Impact factor: 3.641